News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018

Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System

Late-breaker data highlight reduction in rate of inappropriate shocks with sensing filter

Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System

May 16, 2018 — Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of inappropriate shocks using the Smart Pass sensing filter with the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System. The real-world data were presented during a late-breaking clinical trial at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions, May 9-12 in Boston. The results demonstrated that when the sensing filter was in use, the rate of inappropriate shocks was reduced to 4.3 percent at one year.

The analysis was also published online in the Heart Rhythm Journal.[1]

The Smart Pass sensing filter is an advanced algorithm within the Emblem S-ICD System that filters out certain signals that are the primary reason for inappropriate shocks, while still accurately detecting ventricular tachycardia or ventricular fibrillation and delivering lifesaving therapy. Study authors evaluated the effect of Smart Pass on shocks in ambulatory patients and found that the filter reduced the risk for the first inappropriate shock by 50 percent and the risk for all inappropriate shocks by 68 percent, without a negative impact on delivery of appropriate shocks.

"The study data validate the clinical benefit of this sensing methodology to significantly reduce inappropriate shocks by the S-ICD," said Tom F. Brouwer, M.D., presenting author, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, The Netherlands. "At one year, the inappropriate shock rate for patients with the Smart Pass filter in use was as low as rates observed in studies with transvenous implantable cardioverter-defibrillators employing modern programming strategies."

The prospective, blinded evaluation reviewed one year of remote monitoring data from 1,984 patients implanted with an Emblem S-ICD System between 2015 and 2016.

The S-ICD was included for the first time in recently updated guidelines from the American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS), which recommend the device for the treatment of patients with ventricular arrhythmias and the prevention of sudden cardiac death.1

For more information: www.bostonscientific.com

 

References

1. Jean-Benoit le Polain de Waroux, Sylvain Ploux, Pierre Mondoly, et al. Defibrillation testing is mandatory in patients with subcutaneous implantable cardioverter–defibrillator to confirm appropriate ventricular fibrillation detection. HeartRhythm. May 2018. Volume 15, Issue 5, Pages 642–650DOI: https://doi.org/10.1016/j.hrthm.2018.02.013

2. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death, Heart Rhythm (2017), doi: 10.1016/j.hrthm.2017.10.036.

Related Content

News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the ...

Home March 25, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
News | Cardiovascular Clinical Studies

February 8, 2022 — A new study is the first to show that a remote cognitive assessment could help with tracking patients ...

Home February 07, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
Subscribe Now